| 著者 |
北, 俊弘
WEKO
8181
e-Rad_Researcher
70315365
| ja |
北, 俊弘
宮崎大学
|
| ja-Kana |
キタ, トシヒロ
|
| en |
Kita, Toshihiro
University of Miyazaki
|
Search repository
Ohmagari, Norio
Saito, Sho
Mukae, Hiroshi
Takazono, Takahiro
Nakada, Taka Aki
Shimada, Tadanaga
Hirai, Yuji
Shindo, Yuichiro
Komiya, Kosaku
Saito, Atsushi
Yamato, Masaya
Homma, Koichiro
Okamoto, Masaki
| en |
Okamoto, Masaki
National Hospital Organization Kyushu Medical Center
|
Search repository
Yamamoto, Yoshihiro
Mutoh, Yoshikazu
Hasegawa, Chihiro
Mori, Nobuaki
| en |
Mori, Nobuaki
National Hospital Organization Tokyo Medical Center
|
Search repository
Nakamura-Uchiyama, Fukumi
Honda, Mitsuru
Tomii, Keisuke
Ishii, Hiroshi
高城, 一郎
WEKO
9840
e-Rad_Researcher
20418841
| ja |
高城, 一郎
宮崎大学
|
| ja-Kana |
タカジョウ, イチロウ
|
| en |
Takajo, Ichiro
University of Miyazaki
|
Search repository
渡辺, 孝二
WEKO
35526
e-Rad_Researcher
30883631
| ja |
渡辺, 孝二
宮崎大学
|
| ja-Kana |
ワタナベ, コウジ
|
| en |
Watanabe, Koji
University of Miyazaki
|
Search repository
北村, 和雄
WEKO
7929
e-Rad_Researcher
50204912
| ja |
北村, 和雄
宮崎大学
|
| ja-Kana |
キタムラ, カズオ
|
| en |
Kitamura, Kazuo
University of Miyazaki
|
Search repository
|
|
内容記述 |
Adrenomedullin (AM) is a bioactive peptide that is strongly induced during severe inflammation, including pneumonia and sepsis, and serves as an organ-protective factor. The plasma concentration of AM is markedly increased in the novel coronavirus disease COVID-19 and is closely related to the severity of the disease and prognosis of patients. We performed two investigator-initiated trials to evaluate the efficacy and safety of AM in patients with moderate-to-severe COVID-19. This multicenter, double-blind, placebo-controlled phase-2a trial evaluated COVID-19 patients with severe (n = 33) and moderate (n = 31) pneumonia in Japan. Patients were randomly assigned to receive either 15 ng/kg/min AM or placebo. The primary endpoint was the duration of mechanical ventilation (MV) for severe pneumonia and oxygen support for moderate pneumonia. The main secondary endpoint was clinical status up to 30 days after the intervention. No differences in primary or secondary endpoints were observed between the AM and placebo groups in patients with severe or moderate pneumonia. In the severe pneumonia group, three patients in the placebo group died due to respiratory failure, and one patient in the AM group died due to respiratory failure. The respiratory function test at 30 days in the moderate pneumonia group tended to be better than that in the AM group and approached significance (p = 0.073). Although mild adverse events caused by the vasodilatory effects of AM were noted, the safety of AM for treating pneumonia was confirmed. In these trials, we did not observe a definitive efficacy of AM in moderate to severe pneumonia. Alternative strategies for the treatment of AM in pneumonia require further research. |
Fulltext (1.8 MB)
.png)
